Mass spectrometry based biomarker discovery, verification, and validation - Quality assurance and control of protein biomarker assays

Carol E. Parker, Christoph H. Borchers

Research output: Contribution to journalReview articlepeer-review

156 Citations (Scopus)

Abstract

In its early years, mass spectrometry (MS)-based proteomics focused on the cataloging of proteins found in different species or different tissues. By 2005, proteomics was being used for protein quantitation, typically based on "proteotypic" peptides which act as surrogates for the parent proteins. Biomarker discovery is usually done by non-targeted "shotgun" proteomics, using relative quantitation methods to determine protein expression changes that correlate with disease (output given as "up-or-down regulation" or "fold-increases"). MS-based techniques can also perform "absolute" quantitation which is required for clinical applications (output given as protein concentrations). Here we describe the differences between these methods, factors that affect the precision and accuracy of the results, and some examples of recent studies using MS-based proteomics to verify cancer-related biomarkers.

Original languageEnglish
Pages (from-to)840-858
Number of pages19
JournalMolecular Oncology
Volume8
Issue number4
DOIs
Publication statusPublished - 1 Jun 2014
Externally publishedYes

Keywords

  • Biomarker discovery
  • Biomarkers
  • Cancer
  • Mass spectrometry
  • Multiple reaction monitoring
  • Plasma or serum
  • Selected reaction monitoring
  • Targeted proteomics
  • Validation
  • Verification

Fingerprint

Dive into the research topics of 'Mass spectrometry based biomarker discovery, verification, and validation - Quality assurance and control of protein biomarker assays'. Together they form a unique fingerprint.

Cite this